Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2023.11.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integration of physical and mental health services for children and young people with eating disorders and functional symptom disorders: discrete choice experiment.
BMC Health Serv Res
January 2025
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.
Background: Given the increasing recognition of the value of greater integration of physical and mental health services for children and young people, we aimed to evaluate preferences among parents for the characteristics associated with integrated health service provision for two conditions (eating disorders, functional symptom disorders).
Methods: Two discrete choice experiments (DCEs) were conducted, using electronic surveys. Participants were adult parents of children and young people.
Relationship between BMI, indicators of lipid metabolism and diabetic neuropathy: a Mendelian randomization study.
Diabetol Metab Syndr
January 2025
First Central Clinical Medical Institute, Tianjin Medical University, Tianjin, China.
Background: To identify the relationship between BMI or lipid metabolism and diabetic neuropathy using a Mendelian randomization (MR) study.
Methods: Body constitution-related phenotypes, namely BMI (kg/m), total cholesterol (TC), and triglyceride (TG), were investigated in this study. Despite the disparate origins of these data, all were accessible through the IEU OPEN GWAS database ( https://gwas.
Online health information seeking behavior among breast cancer patients and survivors: a scoping review.
BMC Womens Health
January 2025
School of Nursing, Fudan University, 305 Fenglin Road, Shanghai, 200032, China.
Purpose: This scoping review aims to summarize online health information seeking (OHIS) behavior among breast cancer patients and survivors, identify research gaps, and offer insights for future studies.
Methods: Following Arksey and O'Malley's framework, we conducted a review across PubMed, Web of Science, CINAHL, MEDLINE, Cochrane, Embase, CNKI, Wanfang Data, and SinoMed, covering literature from 1 January 2014 to 13 August 2023. A total of 1,368 articles were identified, with 33 meeting the inclusion criteria.
Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells.
J Transl Med
January 2025
Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, No. 4 Bei Jing Road, Yunyan District, Guiyang, 550004, Guizhou, China.
Background: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in the treatment of lymphoma for providing a more valuable reference for clinicians.
View Article and Find Full Text PDFProminent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Exp Hematol Oncol
January 2025
Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, China.
Background: Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited.
Methods: This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL between November 2020 and November 2023 (ChiCTR2100053871). Key endpoints included the adverse event incidence, overall survival (OS), and leukemia-free survival (LFS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!